Moreover, unlike C-reactive protein (CRP) and procalcitonin (PCT), these markers are actual pathway mediators and therefore represent “druggable” targets to improve the outcome of life-threatening infections [30, 40, 41]. This evidence concerns the gene CRP and infection.